Medicine News

• Update On NVA237 And QVA149 For Chronic Obstructive Pulmonary Disease
  Fri, 23 October 2009
  Sosei Group Corporation (Sosei; TSE Mothers Index: 4565), announces that the Phase III trials with NVA237, which commenced in June 2009, are proceeding to plan. Initiation of Phase III studies with QVA149 is now expected to occur during 2010. Receipt of the associated milestone payment of 7.5m is therefore expected during th ...
• AcelRx Announces Positive Results From A Phase 2 Study Of ARX-03, A Sufentanil/Triazolam ...
  Fri, 23 October 2009
  AcelRx Pharmaceuticals, Inc. announced positive results from a Phase 2 clinical trial of ARX-03, a proprietary sublingual dosage form combining an opioid, sufentanil, with a benzodiazepine, triazolam. ARX-03 is designed to address the current unmet need for a non-invasive product to provide mild sedation, anxiolysis and anal ...
• TargeGen Announces Successful Completion Of Clinical Trial Of JAK2 Inhibitor TG101348 In ...
  Fri, 23 October 2009
  TargeGen, Inc. announced that the Company has successfully completed a 59 patient, multicenter clinical trial of TG101348, an oral, potent, and highly selective inhibitor of JAK2 in patients with myelofibrosis. There are no currently approved specific therapies for myelofibrosis (MF), polycythemia vera (PV), or essen ...
• New Study On Vyvanse(R) (lisdexamfetamine Dimesylate) Capsules CII Shows Administration ...
  Fri, 23 October 2009
  Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, announced new data about the pharmacokinetics of its Attention-Deficit/Hyperactivity Disorder (ADHD) medication, Vyvanse (lisdexamfetamine dimesylate) Capsules CII, which showed that Vyvanse provided similar concentrations of its active medi ...
• Sinovac Receives Certificate Of Approval To Distribute PANFLU.1 (H1N1) In Mexico
  Fri, 23 October 2009
  Sinovac Biotech Ltd. (NYSE Amex: SVA), a leading developer and provider of vaccines in China, today announced that it has received a Certificate of Approval from the Secretaria de Salud to distribute PANFLU.1, its H1N1 pandemic influenza (swine flu) vaccine, in Mexico. The certificate is valid through October 13, 2014. Labor ...
• Zogenix And Astellas Announce Data Published Showing The Benefits Of SUMAVEL(TM) DosePro ...
  Fri, 23 October 2009
  Zogenix, Inc. (Zogenix), a privately held pharmaceutical company, and Astellas Pharma US, Inc. (Astellas) announced that positive results from two clinical studies of new SUMAVEL DosePro (sumatriptan injection) needle-free delivery system will be published in the November 2009 issue of Headache. SUMAVEL DosePro, was recently ...
• The Honorable Al Gore To Deliver Keynote Address At 2010 BIO International Convention
  Fri, 23 October 2009
  The Biotechnology Industry Organization (BIO) announced that Former U.S. Vice President Al Gore will be a keynote speaker at the 2010 BIO International Convention, which will take place May 3-6 at McCormick Place in Chicago, Ill. Mr. Gore is scheduled to speak on Wednesday, May 5 from 1:00 p.m. to 1:30 p.m. His speech ...
• BIO Welcomes West Virginia BioScience Association To Industry Council
  Fri, 23 October 2009
  The Biotechnology Industry Organization (BIO) announced that a newly-formed bioscience organization in West Virginia agreed to join the Council of State Bioscience Associations (CSBA), an autonomous council operating within BIO. We are pleased to welcome the
• EU Policies Threaten Developing Countries Drug Supplies, Report Says
  Thu, 22 October 2009
  A report, released Tuesday, from Oxfam International and Health Action International says the EU is putting big drug companies' interests ahead of millions of people in developing countries who do not have access to essential medicines,
• Pharmaceutical Company Coupons To Help Patients Buy Drugs May Raise Insurance Premiums
  Thu, 22 October 2009
  Drug companies use coupons to get patients to choose name-brand products -- which are often more expensive -- by subsidizing a patient's high copay. The practice hides a drug's true costs from consumers.